Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: efficacy and safety results from an open-label, Phase 3 trial
J Dermatol 2024;00:1–15. doi: 10.1111/1346-8138.17074
Week 16 coprimary endpoints of PASI 75 response and sPGA score improved in the majority of patients and was overall maintained through week 52. Deucravacitinib therapy was also associated with a low AE rate. This study presented results from the POETYK PSO-4 trial on the safety and efficacy of deucravacitinib 6mg QD in Japanese patients with psoriasis.
Analysis of the 74 participants was split depending on diagnosis of plaque, generalised pustular, or erythrodermic psoriasis. Plaque psoriasis patients represented the largest cohort (n=63) and experienced the greatest alleviation of symptoms as measured by PASI response and sPGA score.
Keywords:
